Trump's Fortune Slides

Three weeks ago, Donald Trump's Truth Social debuted in the stock market. This surged his net worth from $2.3 billion to $6.4 billion as shares peaked near $80.

By April 16, Trump's fortune plummeted to $3.7 billion due to a 61% drop in his company’s stock this month alone.

Trump Media's market value has decreased from over $10 billion to below $5 billion in just two weeks. Moreover, Trump Media announced a new streaming platform.

Regulatory constraints prevent Trump from capitalizing on his Trump Media investment for at least 5 more months.

Source: Read More

Rates Higher for Longer?

As inflation remains higher than expected, Federal Reserve Chair Jerome Powell has indicated that interest rate cuts will likely be postponed.

Powell stressed the importance of maintaining steady rates to manage inflation effectively. Which has not shown signs of significant decline since last year's rapid drop.

The current data does not boost confidence in a quick resolution. Recent reports confirmed the economy's robust growth and persistent high inflation

All points suggest that borrowing costs will remain elevated for an extended period.

Source: Read More

Tesla Hits the Brakes

Tesla is slashing its workforce by over 10% in the United States and China.

Elon Musk highlighted severe layoffs across sales, tech, and engineering sectors.

This downsizing is part of a broader trend where Tesla battles not only falling demand but also a price war in China, competing against giants like BYD.

In addition, global vehicle deliveries have dropped for the first time in nearly four years.

Source: Read More

The Rise of Personalized Cancer Vaccines

The American Association for Cancer Research (AACR) announced exciting developments in personalized cancer vaccines.

By identifying mutated proteins called "neoantigens" unique to each patient's cancer, these vaccines train the immune system to recognize and destroy cancer cells effectively.

This approach is not preventative; rather, it aims to eliminate residual cancer cells post-treatment and reduce recurrence risks.

Moderna, BioNTech and Genetech have reported positive responses from trials on head, neck and pancreatic cancer patients.

Source: Read More

And by the way ... want to share this email with your friends? Click the link below and I will take care of the rest.
Forward to a Friend